Key result
ACEi, ARBs, and alpha-blockers linked to ~8% lower new-onset diabetes risk in hypertensive women with CAD.
Why the study?
Do different classes of antihypertensive drugs alter the risk of new-onset diabetes in female patients with hypertension and coronary artery disease?
Population
20,108 female patients with hypertension and coronary artery disease (CAD)
Comparison
Various antihypertensive drug classes vs Nonusers of the respective antihypertensive drugs
Design
Cohort
Follow-up
6 years
Authors
Loading...
Should not change practice yet; hypothesis-generating for antihypertensive effects on new-onset diabetes in women with CAD.
Cohort (n=20,128)
Do different classes of antihypertensive drugs alter the risk of new-onset diabetes in female patients with hypertension and coronary artery disease?
Odds Ratio: 0.92 (95% CI 0.84–1)
p-value: p=0.044
In women with hypertension and coronary artery disease, ACE inhibitors, ARBs, and alpha-blockers are associated with a lower risk of new-onset diabetes, while diuretics, beta-blockers, and calcium channel blockers are associated with an increased risk.
Liou et al. (2015) conducted a cohort in Hypertension and Coronary Artery Disease (n=20,128). Antihypertensive drugs (ACE inhibitors, ARBs, alpha-blockers, diuretics, beta-blockers, CCBs) vs. Nonusers was evaluated on New-onset diabetes (OR 0.92, 95% CI 0.84-1.00, p=0.044). In female patients with hypertension and coronary artery disease, ACE inhibitors (OR 0.92), ARBs (OR 0.92), and alpha-blockers (OR 0.88) were associated with a decreased risk of new-onset diabetes compared to nonusers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: